XERS
Xeris Biopharma Holdings, Inc.
Next earnings Aug 5, 2026 · consensus $0.00 EPS, $92.1M rev
Last earnings +4.1% on 2026-05-07
$7.20
▲ +4.35%$7.20▲ +58.59%
over 1Y
L $4.51EODHDH $9.90
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today+4.3%
1W+4.3%
1M+15.0%
3M+36.1%
YTD-2.0%
1Y+58.6%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Buy
Revenue grew 43.7% YoY; but thin net margin (0.2%).
Xeris Biopharma Holdings, Inc. shows $292M in FY2025 revenue (+43.7% YoY), a 0.2% net margin, and 4.0% ROE.
Sources: SEC EDGAR (CIK 0001867096, latest 10-Q filed 2026-05-07) · EODHD · as of 6/24/2026, 10:04:20 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.